MedTrace Logo

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2022-12-22

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.

Conditions

Interventions

DRUG

CyclASol topical ocular, eye drops

Cyclosporine A solution in vehicle

DRUG

Vehicle topical ocular, eye drops

Vehicle

Sponsors & Collaborators

  • Novaliq GmbH

    lead INDUSTRY

Principal Investigators

  • Sonja Kroesser, PhD · Novaliq GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2018-05-22
Completion
2018-06-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03292809 on ClinicalTrials.gov